### Intangible Assets Valuation

Dr. Daniel Sava Dr. Brian More

Mathys & Squire Consulting



WIPO WORLD INTELLECTUAL PROPERTY ORGANIZATION

#### Contents

- Introduction
- Fundamentals of Intangible Assets Valuation
- Methodologies and their limitations
- Advanced Income approach methods & key parameters
- Work through academic specific examples
- Q&A; Wrap-up

#### Dr. Daniel Sava

IP commercialization professional

PhD in Chemistry (Materials Science, Life Sciences)

Financial Modelling Valuation Analyst (FMVA®)



### Dr. Brian More

IP commercialization professional

PhD in nuclear physics (nuclear structure)

MBA in Technology Transfer and Innovation



#### Introduction

Objective – Clear and key considerations for valuation of IP in an academic/technology development environment;

Broad audience – different levels of IP valuation understanding

Discussion! – Always interrupt for questions

## Fundamentals of Intangible Assets Valuation

Dr. Daniel Sava



Understanding the monetary value of the intangible asset (intellectual

property) at a specific time.



## Why?

#### VISUAL CAPITALIST DATASTREAM

#### TANGIBLE **vs** INTANGIBLE ASSETS

Intangible assets currently account for **90%** of the S&P 500's total assets.



WIPO FOR OFFICIAL USE ONLY

#### When?

When do you want your IP/IA valued?



### When?

Transactional

- Transaction pricing license, sale, purchase
- Financing fundraising, collateral based
- Tax requirements
- Liquidation/Re-organisation
- Litigation

No	tal	tio	na	

- Strategic planning
- Insurance purposes
- Management information purposes
- Identification of commercialisation opportunities



Accounting standards - International Financial Reporting Standards (IFRS) & Generally Accepted Accounting Principles (GAAP)

**Intangible assets** – IFRS – International Accounting Standards (IAS) 38 – "An intangible asset is an identifiable non-monetary asset without physical substance. Such an asset is identifiable when it is separable, or when it arises from contractual or other legal rights. Separable assets can be sold, transferred, licensed, etc."

Intangible assets – US GAAP – Accounting Standards Codification (ASC) 350 –

"Intangible assets are assets (not including financial assets) that lack physical substance."

#### What?



What are the usual types of assets you want valued?

What?

Registered/unregistered IP

- Patents
- Trademarks
- Designs
- Copyright
- Trade secrets/know-how

#### Other intangibles

- Contract intangibles
- Customer intangibles
- Data processing intangibles
- Human capital intangibles
- Marketing intangibles
- Goodwill





- License/Spin-out
- Strategic decision
- IP transfer
- IP based financing



- IP ownership
- IP related agreements (NDAs, MTAs, Collaboration Agreements, etc.)
- Cross check IP information databases legal status; fees, remaining life-time
- IP prosecution and litigation (if any) history
- IP protection and respective products; Competitors & IP landscape



- What is the Unique Selling Point (USP)/Value proposition of the IP?
- What is the competitive advantage?
- What is the size of the market?
- What is the regulatory landscape?
- Pricing, adoption, etc.



- Analyse all available financial reports
- Revenue modelling (adoption, pricing, growth rates, etc.)
- Discount rate, royalty rate, financial margins (EBIT,  $\Delta$ WC, etc,), tax rate.
- Timing of Cash Flows and valuation
- Scenarios and sensitivity



- Integrate all information
- Check for cohesive story and assumptions
- Check calculations especially units



Check all information as close as possible to the source!

- Interviews with clients/academics
- Interviews with people within the industry of the IP
- IP checks read through agreements; information public databases, etc.
- Habit to challenge the information (devil's advocate role) ask for sources

#### Valuation approaches

**Business valuation techniques** 

- Asset Approach (fair market value of net assets) cost approach
- Intrinsic Value (Income Approach) Discounted Cash Flows (DCF)
- Relative Value (Market Approach) Public company comparable/Precedent transactions





### Valuation methods

Cost approach (asset approach)

• Cost to reproduce

Market approach (sales comparison approach)

Use comparable IP
transactions

Income approach

 Future potential income

Cost to replace

## Methodologies and their limits

Dr. Daniel Sava

#### Cost approach methods

Cost to reproduce (Cost to develop)

• Estimated cost to make an exact duplicate or replica of the IP at current prices (date of the valuation)

Cost to replace (Cost of reasonable alternatives)

• Estimated cost to make an equivalent utility asset of the IP **at current prices** (date of the valuation)

#### Cost to reproduce

Minimum value of patent right = Cost of developing technology + Patenting legal costs

Price of patent right = Minimum value of patent right + Reasonable profit margin + Entrepreneur's/Owner's incentive (opportunity cost)



Maximum price an acquirer would pay for the IP asset = cost of obtaining a reasonable IP right alternative

#### Cost approaches – key considerations

Data available for analysis – components of cost (Material, Labor, Overhead, Developer's profit, Opportunity Cost/Entrepreneurial incentive)

At current prices – bringing everything to valuation date's prices

- Adjust for inflation
- Adjust for obsolescence
  - Physical obsolescence
  - Functional obsolescence
  - Technological obsolescence
  - Economic obsolescence

#### Cost approaches – limitations

- Disregards the creativity/innovation of the IP
- Hard to properly quantify all the time and advancement effects
- Does not take into account the future (earning) potential of the IP

### Cost approach - example

#### Totals of historical costs

Inflation rate	6%	Tax rate	25%					
Obsolescence	15%	Discount rate	15%					
Profit	10%	Tax amortisation period	15					
Opportunity cost	10%	Annuity	5.8473701					
		TAB factor	0.10797943					
			2018	2019	2020	2021	2022	2023
		Materials (Prototypes)	\$0	\$0	\$20,000	\$75,000	\$0	
		Labor	\$150,000	\$150,000	\$150,000	\$150,000	\$150,000	
		Overhead	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	
		Other costs	\$10,000	\$15,000	\$5,000	\$30,000	\$30,000	
		Total costs	\$177,018	\$182,019	\$192,020	\$272,021	\$197,022	
Adjustments								
		Total costs	\$177,018	\$182,019	\$192,020	\$272,021	\$197,022	\$0
		Profit & Opp. Cost adj.	1.20	1.20	1.20	1.20	1.20	1.20
		Inflation adj.	1.34	1.26	1.19	1.12	1.06	1.00
		Obsolescence adj.	0.50	0.57	0.66	0.76	0.87	1.00
		Adjusted costs	\$141,331.45	\$157,663.10	\$180,447.88	\$277,331.84	\$217,923.46	\$0.00
		Total reproduction costs	\$974,697.73					
		Тах	\$243,674.43					
		After tax reproduction costs	\$731,023.30					
		Tax Amortisation Benefit	\$78,935.48					

Fair value

\$809,958.78

#### Market approach methods

Value of IP – derived – comparable IP transactions (same industry, same IP characteristics (size of portfolio, geography, IP landscape), market and competitor dynamics, etc.)

Sales transaction method – Multiple approach (similar to business valuation)

Licensing transaction – Royalty rate comparables – used in Relief from Royalty method (a mixture of market approach with income approach)

### Market approach limitations

- No "liquid" market for IP transaction (no equivalent of stock market for IP)
- Each piece of IP is unique remaining life and stage of IP, size, competitive market and IP landscape
- Portfolio effect (rarely does a piece of IP transact on its own)
- Survivorship bias

# Market approach methods – Royalty rate benchmark

Advanced Agreement Search							
#	FILTER				STEP COUNT	RESULT COUNT	
1	Full Text carbon capt* OR carbon dioxide OR sequestr* OR carbon util*		🗷 Edit 🛛	8 Remove	683	683	
AND 2	IP Type PATENT TECHNOLOGY	KNOW HOW TRADE SECRET	🗷 Edit 📢	8 Remove	9,700	357	
AND NOT 3	IP Type BRAND CONTENT LOGO SLOGAN TRADEMARK	CUSTOMER LIST DOMAIN NAME SYMBOL WORKS OF AUTHORSHIP	C Edit	Remove	18,851	244	
AND 4	Effective Date AFTER 01/01/2010		🗭 Edit 🛛	8 Remove	5,329	39	
Use Boolean	Logic	hle in the linear logical operators				TOTAL COUNT	
ose boolean logit	s when you need to use more complicated logic that what is availa	iste in the linear logical operators.				39	

Carbon capture technology (patent portfolio) – with no patents yet granted

## Market approach methods – Royalty rate benchmark

Year	Licensor	Licensee	IP right	Territory	Base	Royalty	Restrictions	
15/04/ 2021	Euacentrix LLC	Boon Industries Inc.	IP covering proprietary technology – Proprietary formula (CIO <sub>2</sub> + water) & make use Proprietary Equipment	Worldwide	dwide Net Sales 5%		Exclusive; For all application and uses	
19/11/ 2020	Digital Research Solutions Inc.	JANGIT Enterprises Inc.	Patent (US 10572726 (digital media document summarizer) + associated know-how	Worldwide	Net Sales	6%	Exclusive, Solely for field of Summarization, Consolidation and educational software	
04/12/ 2019	Tortec Forschungsinstit ut gmbh	Tortec Titan+	Exploit the technology (List of 8 patents (Ukraine, Russia) + technologies, patents, designs, processes, formulas, know-how, technical data, etc.) to produce TORtec products.	of 8 patents (Ukraine, Russia) + s, processes, formulas, know-how, Worldwide Net Income 10% produce TORtec products.		10%	Exclusive, Perpetual, Irrevocable	
21/04/ 2015	SG Blocks Inc	Red Cardinal Holdings	Proprietary method and technology for construction of buildings	Worldwide	Net Sales	10%	Non-exclusive USA, EU Exclusive – The world – (USA+EU)	
01/08/ 2011	Temple University	Save the world air, inc.	Patent rights (Patent portfolio – Method for Reduction of Crude oil viscosity – USA, Brazil, Canada, UK, China, Indonesia, Mexico, Nigeria, Norway, Russia, Arab Emirates- granted only in UK and Nigeria) and technical information for making, selling, using, importing Licensed product	Worldwide	Net Sales	7% for (first \$20m sales, sliding scale to 4% for >\$100m	Exclusive	
12/07/ 2010	CEFCO Global Clean Energy, Ilc/CEFCO LLC	Peerless, LLC	CEFCO Process (Patent US20080250715+ know-how) in the field of "air quality control systems for post-combustion gases, including air filtration, air emissions control, carbon emission and capture and air pollutants recovery, and the production of end-products, including chemicals, fertilizers, fuels, and metals and minerals, from the products of such filtration, control, capture or recovery process."	USA	Gross Revenue Sales	5%	Exclusive, 10 years	
09/12/ 2014	Rice University	Tubz, LLC	Patent family (USA, Europe, Israel, South Korea) - Graphene-CNT Hybrid Material and Use as a Supercapacitor Electrode	Worldwide	Adjusted Gross Sales	3% +other payments	Exclusive, Field of use (consumer electronics (including without limitation mobile electronics, mobile telephones/smartphones, tablets, and wearable electronics), nano electronic technologies, electric vehicles, energy storage, and medical devices.)	

#### Income approach methods

Determine the value of the IP – present value of the future income (cash

flow, cost saving)

Direct methods

- Discounted cash flow (cost savings/price premium (product vs generic))
- Relief from Royalty (Royalty Savings)
- Premium profit/With or without (Comparative Income differential; Incremental Cashflow)
- Others Greenfield,

Indirect methods

- Residual Multi-period excess earnings
- Residual Profit split method

#### Income approach methods - example

Example DCF - cost saving or premium profit. - Trade secret (process) - indefinite lifetime

Example for relief from royalty – Patent portfolio – with remaining lifetime 15 years

Example for multi period excess earnings – Creative work (Game) – with remaining lifetime (life of author + 70 years)

#### Income approach methods – DCF – cost savings

#### **Cost savings**

	Average Competitor COGS	35%	Average saving for technology Terminal growth rate Tax rate			У	10%		
	Average COGS with efficient technology	25%					1%		
	Industry growth rate	5%					25%		
	Discount rate	20%	Fi	inancial Year E	End	:	31/12/2023		
	Tax amortisation period	25	V	aluation Date		:	29/08/2023		
	Annuity	4.947587	Fi	First cashflow			31/12/2023		
	TAB factor	0.0520511							
			2023	2024	2025	2026	2027	2028 T	erminal
	Revenues		\$15,000	\$15,750	\$16,538	\$17,364	\$18,233	\$19,144 \$	19,335.67
	Saved costs		\$1,500	\$1,575	\$1,654	\$1,736	\$1,823	\$1,914	\$1,934
Net Pr	resent Value								
	Saved costs		\$1,500	\$1,575	\$1,654	\$1,736	\$1,823	\$1,914	\$1,934
	Taxes		-\$375	-\$394	-\$413	-\$434	-\$456	-\$479	-\$483
	After tax saved costs		\$1,125	\$1,181	\$1,240	\$1,302	\$1,367	\$1,436	\$1,450
	Partial period adjustment		0.34	1	1	1	1	1	
			\$381	\$1,181	\$1,240	\$1,302	\$1,367	\$1,436	
	Terminal value							\$7,632	
			\$381	\$1,181	\$1,240	\$1,302	\$1,367	\$9,068	
	Years for discounting		0.34	1.34	2.34	3.34	4.34	5.34	
	Discount factor		94%	78%	65%	54%	45%	38%	
	Present value of saved costs		\$358	\$925	\$810	\$709	\$620	\$3,426	
	Net present value		\$6,848						
	Tax amortization benefit		\$356						
	Fair value		\$7,204						
## Income approach methods – Relief from Royalty

Saved Royalties

		Ro	oyalty Rate			3%		
		Те	erminal growth	n rate		-10%		
		Та	x rate			25%		
Discount rate	20%	Fir	nancial Year E	nd	3	1/12/2023		
Tax amortisation period	15	Va	luation Date		2	9/08/2023		
Annuity	4.6754726	Fir	rst cashflow		3	1/12/2023		
TAB factor	0.0845099							
		2023	2024	2025	2026	2027	2028	Terminal
Revenues		\$1,500	\$2,750	\$4,000	\$5,000	\$6,750	\$7,250	\$6,525.00
Royalties		\$45	\$83	\$120	\$150	\$203	\$218	\$196

Net Present Value

Royalties	\$45	\$83	\$120	\$150	\$203	\$218	\$196
Taxes	-\$11	-\$21	-\$30	-\$38	-\$51	-\$54	-\$49
After tax royalties	\$34	\$62	\$90	\$113	\$152	\$163	\$147
Partial period adjustment	0.34	1	1	1	1	1	
	\$11	\$62	\$90	\$113	\$152	\$163	
Terminal value						\$489	
	\$11	\$62	\$90	\$113	\$152	\$653	
Years for discounting	0.34	1.34	2.34	3.34	4.34	5.34	
Discount factor	94%	78%	65%	54%	45%	38%	
Present value of saved costs	\$11	\$48	\$59	\$61	\$69	\$247	
Net present value	\$495						
Tax amortization benefit	\$42						
Fair value	\$536						
	WIPO FOR OFFICIAL US	F ONI Y					

## Income approach methods – Multi period excess

earnings Mut

od excess earnings								
CACs	3.5%	EB	BIT margin			15%		
		Те	erminal growth	n rate		4%		
		Та	ix rate			25%		
Discount rate	20%	Fir	nancial Year E	nd	3	1/12/2023		
Tax amortisation period	25	Va	aluation Date		2	9/08/2023		
Annuity	4.947587	Fir	rst cashflow		3	1/12/2023		
TAB factor	0.0520511							
		2023	2024	2025	2026	2027	2028	Terminal
Revenues		\$1,500	\$2,750	\$4,000	\$5,000	\$6,750	\$7,250	\$7,540.0
EBIT		\$225	\$413	\$600	\$750	\$1,013	\$1,088	\$1,13

Net Present Value of excess earnings							
EBIT	\$225	\$413	\$600	\$750	\$1,013	\$1,088	\$1,131
Taxes	-\$56	-\$103	-\$150	-\$188	-\$253	-\$272	-\$283
Contributory asset charges	-\$53	-\$96	-\$140	-\$175	-\$236	-\$254	-\$264
Net excess earnings	\$116	\$213	\$310	\$388	\$523	\$562	\$584
Partial period adjustment	0.34	1	1	1	1	1	
	\$39	\$213	\$310	\$388	\$523	\$562	
Terminal value						\$3,652	
	\$39	\$213	\$310	\$388	\$523	\$4,214	
Years for discounting	0.34	1.34	2.34	3.34	4.34	5.34	
Discount factor	94%	78%	65%	54%	45%	38%	
Present value of saved costs	\$37	\$167	\$202	\$211	\$237	\$1,592	
Net present value	\$2,446						
Tax amortization benefit	\$127						
Fair value	\$2,574						
	WIPO FOR OFFICIAL US	SE ONLY					

# Which method should I choose?

	Relief from Royalty	MPEE	With or without	Greenfield	DCF (cost saving/price premium)	Cost method
Brand/ Trademark	✓		✓		✓	
Trade secret/ Know-how	1	✓			$\checkmark$	
Patents/ Technology/Database/ Mask works	✓	✓			✓	
Software	✓	1			✓	1
Copyright (teaching material/ artistic work /procedures) Designs	✓	✓		✓		✓
License/Contract			1	$\checkmark$		

# Not an exact science – Scenarios & Sensitivity analysis

#### DCF cost savings

#### Relief from Royalty

			Di	scount rate						Dis	count rate		
ഇ		15.0%	17.5%	20.0%	22.5%	25.0%			15.0%	17.5%	20.0%	22.5%	25.0%
avir	5.0%	\$5 <i>,</i> 021	\$4,198	\$3,602	\$3,151	\$2,799	D	2.0%	\$470	\$407	\$358	\$317	\$284
S S	7.5%	\$7 <i>,</i> 531	\$6,297	\$5 <i>,</i> 403	\$4,727	\$4,199	rat	2.5%	\$588	\$509	\$447	\$396	\$354
golo	10.0%	\$10,042	\$8,396	\$7,204	\$6 <i>,</i> 303	\$5 <i>,</i> 598	alty	3.0%	\$705	\$611	\$536	\$476	\$425
hnc	12.5%	\$12 <i>,</i> 552	\$10,496	\$9,006	\$7,879	\$6,998	sove	3.5%	\$823	\$713	\$626	\$555	\$496
Tec	15.0%	\$15,063	\$12,595	\$10 <i>,</i> 807	\$9 <b>,</b> 454	\$8,397	Ľ.	4.0%	\$940	\$815	\$715	\$634	\$567

#### MPEE

		Dis	count rate		
_	15.0%	17.5%	20.0%	22.5%	25.0%
10.0%	\$2,070	\$1,627	\$1,328	\$1,115	\$955
12.5%	\$3,040	\$2,389	\$1,951	\$1,638	\$1,403
15.0%	\$4,011	\$3,152	\$2,574	\$2,160	\$1,851
17.5%	\$4,981	\$3,914	\$3,196	\$2,683	\$2,299
20.0%	\$5,952	\$4,677	\$3,819	\$3,205	\$2,747

MPEE	
------	--

		Dis	scount rate		
	15.0%	17.5%	20.0%	22.5%	25.0%
2.5%	\$4,528	\$3,559	\$2,906	\$2,439	\$2,090
3.0%	\$4,270	\$3,355	\$2,740	\$2,300	\$1,970
3.5%	\$4,011	\$3,152	\$2 <i>,</i> 574	\$2,160	\$1,851
4.0%	\$3,752	\$2,949	\$2,408	\$2,021	\$1,732
4.5%	\$3 <i>,</i> 493	\$2,745	\$2,242	\$1,881	\$1,612

EBIT

CAC

# Advanced Income Approach methods & Key parameters

Dr. Daniel Sava; Dr. Brian More

#### **Advanced Income Methods**

Standard income methods

• do not take into account market flexibility/uncertainty

Purpose of advanced methods

- does take into account market uncertainty
- helps with strategic decisions



#### rNPV – risk adjusted Net Present Value

#### Extension of the DCF method – accounting for risk/probability of success

#### rNPV – simple example

Project – InvenTech

Still in development – requires \$50k investment today

1 year – 50% success rate; further \$300k required to launch on market

After launch Revenues are Y2 - \$150k Y3 \$250k Y4 - \$450k Y5 - \$250k Y6 -

\$200k; Cash flow is 40% of Revenues.

Discount rate 15%

# rNPV – simple example

Year	0	1	2	3	4	5	6
Revenue	\$0	\$0	\$150,000	\$250,000	\$450,000	\$250,000	\$200,000
Net CF	-\$50,000	-\$300,000	\$60,000	\$100,000	\$180,000	\$100,000	\$80,000
Success factor	100%	50%	50%	50%	50%	50%	50%
Risk adjusted CF	-\$50,000	-\$150,000	\$30,000	\$50,000	\$90,000	\$50,000	\$40,000
Discount	100%	87%	76%	66%	57%	50%	43%
Risk adjusted present CF	-\$50,000	-\$130,435	\$22,684	\$32,876	\$51,458	\$24,859	\$17,293
rNPV	-\$31,265						

Development of technology – not pre-defined

In reality - many decision points in taking a project to market

InvenTech – instead of the 50% chance of success;

30% chance – great results; (better revenues by 50%)

40% - abandon

30% - more development (another \$75k required) – which results 67% - good results, 33% abandon

			Year		1	2	3	4	5		6	
			Revenue	9	60	\$225,000	\$375,000	\$675,000	\$375,0	00 \$3	00,000	
Great r		Proot results	Net CF	-\$30	0,000	\$90,000	\$150,000	\$270,000	\$150,0	00 \$1	20,000	
		NPV1	Discount	10	0%	87%	76%	66%	57%	<b>,</b>	50%	
			Present CF	-\$30	0,000	\$78,261	\$113,422	\$177,529	\$85,70	63 \$5	9,661	
	2004		NPV1	\$21 <i>4</i>	4,636							
	30%											
					Year	2	3	4	5	6	7	
					Revenue	e \$0	\$150,000	\$250,000	\$450,000	\$250,000	\$200,00	)0
			Good results	NPV2	Net CF	-\$300,000	\$60,000	\$100,000	\$180,000	\$100,000	\$80,00	0
Initial R&D	Further R			Discount	t 100%	87%	76%	66%	57%	50%		
	30%				Present C	CF -\$300,000	\$52,174	\$75,614	\$118,353	\$57,175	\$39,77	4
					INPV2	<b>\$43,091</b>						
		33%	Abandon									
	40%		Abandon									
		Abandon										
YO	Y1	Y2										

WIPO



Year	1	2
Revenue	\$0	\$0
Net CF	-\$75,000	\$43,091
Success factor	100%	67%
Risk adjusted CF	-\$75,000	\$28,871
Discount	100%	87%
Risk adjusted present CF	-\$75,000	\$25,105
NPV	-\$49,895	

**WIPO** 



## rNPV – decision tree vs simple risk adjustment

Year	0	1	2	3	4	5	6
Revenue	\$0	\$0	\$225,000	\$375,000	\$675,000	\$375,000	\$300,000
Net CF	-\$50,000	-\$300,000	\$90,000	\$150,000	\$270,000	\$150,000	\$120,000
Success factor	100%	30%	30%	30%	30%	30%	30%
Risk adjusted CF	-\$50,000	-\$90,000	\$27,000	\$45,000	\$81,000	\$45,000	\$36,000
Discount	100%	87%	76%	66%	57%	50%	43%
Risk adjusted present CF	-\$50,000	-\$78,261	\$20,416	\$29,588	\$46,312	\$22,373	\$15,564
NPV1	\$5,992						

#### rNPV = -\$50,000 + (30%× \$214,636)×0.87 = <u>\$5992</u>

Y0

#### Monte Carlo

For traditional DCFs – people use scenarios – worst case, average case, best case (assumptions for each case)

Monte Carlo – simulate the probability of a range of case

Example – Simulate a normal distribution for number of units sold, price of product, discount rate and royalty rate (based on mean & std. deviation)



#### Monte Carlo

Result a distribution of NPV (or Fair Values) for the IP.





A real option gives the owner the right, but not the obligation to do something;

From finance – Call option (Option to buy asset at an agreed price); Put option (Option to sell an asset at an agreed price)

Different options – option to defer, option to expand or contract, option to abandon or licence, option to switch, option to stage investments, options to grow.

For IP valuation – option to abandon once a project is not profitable anymore is the most used.



From a mathematical point of view – 4 methods to value an option:

- Formula
- Trees
- Simulations
- Finite differences

IP valuation – Trees (binomial) and Formula (Black Scholes) – the most used.

# Real options – binomial tree

Similar to decision trees – Binomial tree

Main use – valuation of Life Sciences Projects

Changes of Revenues(Cashflows)

Each node – 2 possibilities

Main assumption – Volatility

Steps up down – calculate based on volatility and time interval



Valuation in Life Sciences – A Practical Guide -Boris Bogdan, Ralph Villiger

## Real options – Black Scholes formula

Black Sch	oles formu	ula $C=N(d$	$S_1)S_t - N(d_2)Ke^{-rt}$
С	=	where call option price	$d_1 = rac{\ln rac{S_t}{K} + (r + rac{\sigma^2}{2})t}{\sigma \sqrt{t}} \  ext{and} \ d_2 = d_1 - \sigma \sqrt{t}$
Ν	=	Cumulative distribution functions of the normal distribution (	(Area under the curve)
St	=	spot price of an asset (Current underlying price asset – Pre	sent value of cashflows)
К	=	strike price (exercise price – Cost of development)	
r	=	risk-free interest rate	
t	=	time to maturity (how long to get to market)	
σ	=	volatility of the asset	

**WIPO** 

56



Discount rate

Royalty rate

Success rates

Others

One of the greatest impact on the final valuation results – Starting base

- Market/Industry analysis
- Corresponding product & geography IP
- Competitive landscape market share
- Value proposition/Unique selling point (USP) Pricing

#### Basic modelling – linear growth rate

Year	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032
Revenue	\$1,000,000	\$1,100,000	\$1,210,000	\$1,331,000	\$1,464,100	\$1,610,510	\$1,771,561	\$1,948,717	\$2,143,589	\$2,357,948
Total addressable market	\$10,000,000									
Market share	10%									
Growth rate	10%									

**WIPO** 

#### Basic modelling – comparable growth rates

Growth rates		55%	48%	41%	37%	33%	25%	20%	15%	10%
Year	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032
Revenue	\$200,000	\$310,000	\$458,800	\$646,908	\$886,264	\$1,178,731	\$1,473,414	\$1,768,097	\$2,033,311	\$2,236,642
Total addressable market	\$10,000,000									
Market share	2%									

WIPO

#### More realistic approach – Fisher – Pry model – diffusion of new technologies

Year	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032
Time (t)	0	1	2	3	4	5	6	7	8	9
Market Penetration (MP)	11.92%	18.24%	26.89%	37.75%	50.00%	62.25%	73.11%	81.76%	88.08%	92.41%
Revenue	\$1,192,029	\$1,824,255	\$2,689,414	\$3,775,407	\$5,000,000	\$6,224,593	\$7,310,586	\$8,175,745	\$8,807,971	\$9,241,418
Target market size (SOM)	\$10,000,000									
Shape parameter (β)	0.50		$MP = \frac{1}{1}$ Logistic curve							
Time to 50% (T)	4					1 + e <sup>-</sup>	-p(t-1)			

The larger  $\beta$  – the steeper the curve.

Ideally – model  $\beta$  and T – based on numbers within the industry





Discount rate – rate factor with which future cash flows are discounted to a present value.

\$100 today > \$100 in one year > \$100 in two years, etc. (Time value of money)

#### **Discount rate**

Companies can raise money through debt (borrowing)

or through equity (selling shares)

Investors – want a return for their money

Return for debt < return for equity - Debt is paid first & the remainder goes to shareholders

Weighted average cost of capital (WACC)



Weighted average cost of capital formula

https://www.businessinsider.com/personal-finance/weighted-average-cost-of-capital



For IP assets – Investment – shareholders or potential shareholders

What is their required return? What is the cost of equity?

Risk vs Reward

The riskier the IP – the higher the Reward required



#### Discount rate – theoretical models

Capital Asset Pricing Model (CAPM) -  $R_e = r_f + \beta (r_m - r_f) = r_f + \beta r_p$ 

 $R_e$  – cost of equity;  $r_f$  – risk free rate (US treasuries, UK gilts rates)

 $r_m$  – market required rate of return;  $r_p$  – market risk premium

 $\beta$  – measure of volatility – movement of a stock compared to the stock market as a whole

Advantageous – databases with all parameters

Better suited for bigger companies with diversified IP assets

#### Discount rate – theoretical models

Build up method –  $R_e = r_f + r_p + r_i + r_s + r_c + r_{cp}$ 

 $r_i$  – industry premium,  $r_s$  – size premium,  $r_c$  – country premium,  $r_{cp}$  – company risk

Advantageous – databases with all parameters

Better suited for bigger companies with diversified IP assets

# Discount rate – IP – early stage

IP valuations discount rate

- Not a diversified portfolio (single asset/product more risk)
- High likelihood of failure
- Market/Industry/Regulatory landscapes matter

Investment in IP – very similar to early-stage Venture Capital Investment

#### Discount rate – IP

#### Venture Capital Rates of Return

Stage of development	Required rate of return (%)
Startup	50 - 70
First stage (early development)	40 - 60
Second Stage (expansion)	30 - 50
Third Stage	20 - 35

Intellectual property – Valuation, Exploitation, and Infringement Damages – Russell L. Parr – 5<sup>th</sup> edition 2018

Startup – companies less than 1 year old; First stage – Prototypes developed, scaling up risk high;

Second stage – Product finalised and company growing; Third stage – Companies approaching maturity

#### Discount rate – IP

Venture Capital Rates of Return -  $(1+TR)^T = (1+r)^T/(1-p)$ 

 $TR = [(1+r)^T/(1-p)]^{(1/T)} - 1;$  TR – target return; r- required return; p – probability of failure; T- time to exit

For r = 25%

	10%	20.0%	30.0%	40.0%	50.0%	60.0%	70.0%	80.0%	90.0%	1
1	39%	56%	79%	108%	150%	213%	317%	525%	1150%	1
2	32%	40%	49%	61%	77%	98%	128%	180%	295%	1
3	29%	35%	41%	48%	57%	70%	87%	114%	169%	1
4	28%	32%	37%	42%	49%	57%	69%	87%	122%	1
5	28%	31%	34%	38%	44%	50%	59%	72%	98%	1
 6	27%	30%	33%	36%	40%	46%	53%	63%	83%	
7	27%	29%	32%	34%	38%	42%	48%	57%	74%	
8	27%	29%	31%	33%	36%	40%	45%	53%	67%	
9	26%	28%	30%	32%	35%	38%	43%	49%	61%	1

- -

Royalty rate

Royalty rate – Licensor (owner of IP) – granting rights to Licensee (using the IP)

Licensing agreement – many considerations

- Licensed rights (details of IP)
- Scope of licence (geographies, markets, field of use)
- Exclusivity (exclusive, sole, non-exclusive)
- Financial terms (up-front payments, milestone payments, running royalties,

royalty base, equity compensation, audit clauses, etc.)





WIPO



Non-	Non-	Sole	Sole	Exclusive	Exclusive	Exclusive	Exclusive
exclusive	exclusive	license	License	license	license	license	license
license	license						
Occurrenter	<b>O</b> oon a sura sa ba s	<b>O</b> oo ayyo ya ku y	<b>O</b> oonena kui	Restricted	Worldwide	Restricted	Worldwide
Geography	Geography	Geography	Geography	geograpny	Postriated	geograpny	For all
	_		_		Restricted		
Restricted	Fields of	Fields of	Fields of	Restricted	field of use	For all	fields of
field of use	use	use	use	field of use		fields of	use
						use	



**WIPO**
#### Royalty rate determination

- Rule of thumb 25% of profit (or 5% Net Sales for businesses with 20% profit margin)
- Benchmarking similar transactions or industry averages
- Profit differential analysis (profit with and without access to the IP)
- Profit split Analysis of contributions for allocation of profit royalty rate (ideal)



- Agreements need to be analysed in detail (very time consuming)
  - Granted rights
  - Geography; Field of Use
  - Royalty Base (Gross sales, Net sales, EBITDA, Net Profit, etc.)
  - Related parties vs. Arm's length negotiation
  - Industry, types of companies, etc.

#### Royalty rate determination

Industry	Average	Median	Max	Min	Count
Chemicals	4.7%	4.3%	25.0%	0.1%	78
Internet (incl software)	11.8%	8.8%	50.0%	0.3%	88
Telecom (excl Media)	4.9%	4.5%	15.5%	0.4%	73
Consumer Goods, Retail & Leisure	5.5%	5.0%	28.0%	0.1%	98
Media & Entertainment	9.1%	5.0%	50.0%	2.0%	25
Food Processing	3.2%	2.8%	10.0%	0.3%	38
Medical/Health Products	6.1%	5.0%	77.0%	0.1%	376
Pharma & Biotech	7.0%	5.0%	50.0%	0.0%	458
Energy & Environment	5.0%	5.0%	20.0%	1.0%	107
Machines/Tools	5.2%	4.5%	25.0%	0.5%	90
Automotive	4.3%	3.5%	15.0%	0.5%	59
Electrical & Electronics	4.2%	4.0%	15.0%	0.5%	139
Semiconductors	4.3%	3.0%	30.0%	0.0%	75
Computers & Office Equip	5.3%	4.0%	25.0%	0.2%	73
Software	11.5%	6.8%	70.0%	0.0%	147
Industry Summary	6.40%	4.80%			derived from Rogerty Source

#### Success rate



> >

505

(46%)

307

2<sup>nd</sup> ROUND

3rd ROUND

lote: All numbers based on cohort of companies that raised

Seed in 2008, 2009 or 2010 and disclosed valuations only.

FAIL

то RAISE

442

>>> 119 (11%) >>> 79 (7%)

M&A /

EXIT

(14%)

> > 151





Note: cohorts between 2010-2013. Several companies from these cohorts may still reach exit, which would increase % success.

1. Data is also affected by survival bias: there are many unknown seeded companies that failed and never announced their seed round. Correcting for this would reduce the % success.



EXITED

OVER

\$1B+

EXITED OVER

\$500M+

EXITED

OVER

\$200M+

#### Success rate

	Disease Group	Stage 1	Stage 2	Stage 3	Approval	Cumulative
	Arthritis/Pain	76.90%	38.10%	78.10%	89.10%	20.40%
(	CNS	66.20%	45.60%	61.80%	77.90%	14.50%
Pharma/	CV	62.70%	43.30%	76.30%	84.40%	17.50%
Diatash	GIT	66.80%	49.10%	71.00%	85.90%	20.00%
Biotech	Immunology	64.80%	44.60%	65.20%	81.60%	15.40%
Success	Infections	70.80%	51.20%	79.90%	96.90%	28.10%
000000	Metabolism	47.80%	52.00%	78.90%	92.80%	18.20%
rates	Oncology	64.40%	41.80%	65.40%	89.70%	15.80%
	Ophthalmology	66.00%	39.00%	64.00%	92.00%	15.20%
	Respiratory	63.40%	41.10%	59.90%	76.90%	12.00%
	Urology	50.00%	38.00%	67.00%	79.00%	10.10%
	Women's Health	39.00%	42.00%	48.00%	59.00%	4.60%

Valuation in Life Sciences – A Practical Guide -Boris Bogdan, Ralph Villiger



Valuation date & End of financial year – Adjustments for partial period and cashflows – informs the assumptions;

Tax rate & Tax amortisation benefit

**Contributory Asset Charges** 

EBIT margin

Changes in WC margin

# Work through academic specific examples

Dr. Brian More

# Case study 1 – Valuation of technology (patents + know how)

Carbon capture technology – patent at PCT stage (priority date – Jan 2022) + know-how

ISR report – quite clean + different types of claims

There are a few strong competitors

The team is very experienced and can deliver scale-up; done so with previous technology

No projections, not easy to get the costs of development as was done alongside other things.

#### Case study 1 – Valuation methods

What method would you choose?

Relief from Royalty - easiest to obtain data for

DCF/Greenfield can also work – more data required about EBIT, changes in working capital, investment requirements, depreciation & amortisation.

#### Case study 1 – Revenue modelling

Carbon market – a few established players

https://www.iea.org/energy-system/carbon-captureutilisation-and-storage

Around – 125Mt per year by 2030 (125 million tonnes)

For our example – the technology aims for 1**Mt** by 2033 – Fisher Pry to model the diffusion of the technology.

Price per tonne – PwC – forecasts future carbon offset prices (graph) – assume a \$60



https://www.pwc.co.uk/services/sustainability-climate-change/insights/bullish-sentiment-expected-over-next-decade-for-carbon-markets-globally-latest-trends-and-developments-in 2022.html#:~:text=The%20EU%20and%20UK%20ETS,2026%2D30%20for%20both%20schemes

#### Case study 1 – Revenue modelling

Year	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Time	0	1	2	3	4	5	6	7	8	9	10
Penetration	3.23%	7.24%	15.45%	29.94%	50.00%	70.06%	84.55%	92.76%	96.77%	98.59%	99.39%
Removal Capacity	32	72	154	299	500	701	846	928	968	986	994
Target removal capacity	1,000										
Shape parameter	0.85										
Timeto50%	4										

#### Revenue in thousands)

Penetration	3.23%	7.24%	15.45%	29.94%	50.00%	70.06%	84.55%	92.76%	96.77%	98.59%	99.39%
Carbon removal capacity (kilotonnes)	32.00	72.00	154.00	299.00	500.00	701.00	846.00	928.00	968.00	986.00	994.00
Revenue	\$1,920	\$4,320	\$9,240	\$17,940	\$30,000	\$42,060	\$50,760	\$55 <i>,</i> 680	\$58 <i>,</i> 080	\$59,160	\$59,640

#### Case study 1 – Royalty rate

Year	Licensor	Licensee	IP right	Territory	Base	Royalty	Restrictions
15/04/ 2021	Euacentrix LLC	Boon Industries Inc.	IP covering proprietary technology – Proprietary formula (CIO <sub>2</sub> + water) & make use Proprietary Equipment	Worldwide	Net Sales	5%	Exclusive; For all application and uses
19/11/ 2020	Digital Research Solutions Inc.	JANGIT Enterprises Inc.	Patent (US 10572726 (digital media document summarizer) + associated know-how	Worldwide	Net Sales	6%	Exclusive, Solely for field of Summarization, Consolidation and educational software
04/12/ 2019	Tortec Forschungsinstit ut gmbh	Tortec Titan+	Exploit the technology (List of 8 patents (Ukraine, Russia) + technologies, patents, designs, processes, formulas, know-how, technical data, etc.) to produce TORtec products.	Worldwide	Net Income	10%	Exclusive, Perpetual, Irrevocable
21/04/ 2015	SG Blocks Inc	Red Cardinal Holdings	Proprietary method and technology for construction of buildings	Worldwide	Net Sales	10%	Non-exclusive USA, EU Exclusive – The world – (USA+EU)
01/08/ 2011	Temple University	Save the world air, inc.	Patent rights (Patent portfolio – Method for Reduction of Crude oil viscosity – USA, Brazil, Canada, UK, China, Indonesia, Mexico, Nigeria, Norway, Russia, Arab Emirates- granted only in UK and Nigeria) and technical information for making, selling, using, importing Licensed product	Worldwide	Net Sales	7% for (first \$20m sales, sliding scale to 4% for >\$100m	Exclusive
12/07/ 2010	CEFCO Global Clean Energy, llc/CEFCO LLC	Peerless, LLC	CEFCO Process (Patent US20080250715+ know-how) in the field of "air quality control systems for post-combustion gases, including air filtration, air emissions control, carbon emission and capture and air pollutants recovery, and the production of end-products, including chemicals, fertilizers, fuels, and metals and minerals, from the products of such filtration, control, capture or recovery process."	USA	Gross Revenue Sales	5%	Exclusive, 10 years
09/12/ 2014	Rice University	Tubz, LLC	Patent family (USA, Europe, Israel, South Korea) - Graphene-CNT Hybrid Material and Use as a Supercapacitor Electrode	Worldwide	Adjusted Gross Sales	3% +other payments	Exclusive, Field of use (consumer electronics (including without limitation mobile electronics, mobile telephones/smartphones, tablets, and wearable electronics), nano electronic technologies, electric vehicles, energy storage, and medical devices.)

#### Case study 1 – Royalty rate

What royalty rate should we use for this valuation?

Which do you think is the closest comparable?

In my view – 5<sup>th</sup> agreement is the closest – start from 5% - consider geography, exclusivity, any other existing licences.

How would you adjust if you discover there is already a contract that gives a companies a free non-exclusive world-wide licence?

3.25% - 3.75%

WIPO

#### Case study 1 – Discount rate and risk adjustment

What are the risks for this technology to reach the market?

What are the risks associated with the IP?

How can we account for the risk in the IP valuation?

Either high VC discount rate; or Rate of return of startup (20%) + risk adjustment of revenues (10% success rate)

#### Case study 1 – Other parameters

Tax rate – 25% - usually a good assumption if no information

Terminal growth rate - -7% - the patent expires in 2043

Tax amortisation period – Remaining patent lifetime

Valuation data

End of financial year

#### Case study 1 – Revenues & Inputs

#### **Revenues & Inputs**

		Rc	yalty Rate			3.5%	Si	ucces factor		10%			
Target Capacity for removal (kilotonnes)	1,000	Те	erminal growt	h rate		-7%							
Price per kilotonne	\$60	Та	x rate			25%							
Discount rate	20%	Fir	nancial Year E	ind	3	31/12/2023							
Tax amortisation period	19	Va	luation Date		2	29/08/2023							
Annuity	4.8434957	Fir	rst cashflow		3	31/12/2023							
TAB factor	0.0680682												
		2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	<b>2033</b> 1	erminal
Penetration		3.23%	7.24%	15.45%	29.94%	50.00%	70.06%	84.55%	92.76%	96.77%	98.59%	99.39%	
Carbon removal capacity (kilotonnes)		32.00	72.00	154.00	299.00	500.00	701.00	846.00	928.00	968.00	986.00	994.00	924.00
Revenue		\$1,920	\$4,320	\$9 <i>,</i> 240	\$17,940	\$30,000	\$42 <i>,</i> 060	\$50,760	\$55,680	\$58 <i>,</i> 080	\$59 <i>,</i> 160	\$59,640	\$55 <i>,</i> 440

## Case study 1 – Fair value

#### Net Present Value

Revenues	\$1,920	\$4,320	\$9,240	\$17,940	\$30,000	\$42,060	\$50,760	\$55,680	\$58,080	\$59,160	\$59,640	\$55,440
risk adjusted revenues	\$192	\$432	\$924	\$1,794	\$3 <i>,</i> 000	\$4,206	\$5,076	\$5,568	\$5 <i>,</i> 808	\$5,916	\$5 <i>,</i> 964	\$5,544
Pre tax royalties	\$7	\$15	\$32	\$63	\$105	\$147	\$178	\$195	\$203	\$207	\$209	\$194
Taxes	-\$2	-\$4	-\$8	-\$16	-\$26	-\$37	-\$44	-\$49	-\$51	-\$52	-\$52	-\$49
After tax saved costs	\$5	\$11	\$24	\$47	\$79	\$110	\$133	\$146	\$152	\$155	\$157	\$146
Partial period adjustment	0.34	1	1	1	1	1	1	1	1	1	1	1
	\$2	\$11	\$24	\$47	\$79	\$110	\$133	\$146	\$152	\$155	\$157	\$146
Terminal value												\$539
	\$2	\$11	\$24	\$47	\$79	\$110	\$133	\$146	\$152	\$155	\$157	\$685
Years for discounting	0.34	1.34	2.34	3.34	4.34	5.34	6.34	7.34	8.34	9.34	10.34	11.34
Discount factor	94%	78%	65%	54%	45%	38%	31%	26%	22%	18%	15%	13%
Present value of saved costs	\$2	\$9	\$16	\$26	\$36	\$42	\$42	\$38	\$33	\$28	\$24	\$87
Net present value	\$382											
Tax amortization benefit	\$26											
Fair value	\$408											

Fair value

#### Case study 1 – Sensitivity Analysis

	Discount rate									
	15.0%	17.5%	20.0%	22.5%	25.0%					
2.5%	\$430	\$351	\$291	\$245	\$209					
3.0%	\$516	\$421	\$349	\$294	\$251					
3.5%	\$602	\$491	\$408	\$343	\$293					
4.0%	\$688	\$561	\$466	\$392	\$334					
4.5%	\$774	\$631	\$524	\$441	\$376					

		Discount rate								
		15.0%	17.5%	20.0%	22.5%	25.0%				
	7.5%	\$451	\$368	\$306	\$257	\$219				
ate	10.0%	\$602	\$491	\$408	\$343	\$293				
SS ra	12.5%	\$752	\$614	\$510	\$429	\$366				
ссе	15.0%	\$903	\$737	\$611	\$515	\$439				
Su	17.5%	\$1 <i>,</i> 053	\$859	\$713	\$601	\$512				

## Case study 2 – Software valuation (copyright)

Scientific software for selling to pharma and chemical industry companies

Accounts for cost of development

IP copyright – not patented; no open-source code used

The software comprises 5 modules developed in collaboration between the biotechnology department and the computing department

Use the cost to reproduce at today's prices

#### Financial Data Verified by Accounts

Year	2018	2019	2020	2021	2022	2023
	Inception	Coding	Elaboration	Transition	Transition	Delpoyment
Systems Architect	25,000	5,000	54,000	10,000	5,400	14,000
Sprint Manager	2,000	35,000	46,300	0	0	0
Designer	36,700	10,000	23,670	2,600	0	3,000
Coder	0	176,320	83,250	20,000	12,300	4,320
Penetration testing	0	0	28,900	32,800	25,890	6,000
Overheads	12,740	45,264	47,224	13,080	8,718	5,464
Capital expenditure	28,500			4,630		
Consultancy	20,000	20,000	20,000	20,000	20,000	20,000
Totals	124,940	291,584	303,344	103,110	72,308	52,784
Total Historic Cost	94	48,070				

Accounting year end the 30th of June

#### **Input Parameters for Valuation**

Adjustments	Тах
-------------	-----

Inflation rate	5% pa	Corporation Tax	25%
Obsolescence	10% pa	Tax Amortization period	15 years
Profit	10%	Annuity	5.8473
Opportunity cost	10%	TAB factor	0.10797943
Discount rate	15%		
Valuation date	30/08/2023		

#### Step by Step Calculations

Multiply the annual costs by the profit and opportunity cost to enhance the value = 120%

Totals	124,940	291,584	303,344	103,110	72,308	32,784
Profit + Opportunity	149,928	349,901	364,013	123,732	86,770	39,341
Multiply the new	costs by the i	inflation factor				
Number of days	from the acco	ounting period en	d to the valuation	on date = 61 days	3	
Enhancement fa	ctor = 0.167 t	o increase the co	osts from June to	o August		
For 2023 multipl	y by (1 + 0.05	$) ^ 0.167 = 1.008$	3	C		
For 2022 multipl	y by $(1 + 0.05)$	$) ^{1.167} = 1.059$	)			
Thon continue h	2012	,				

Then continue back to 2018

Totals	124,940	291,584	303,344	103,110	72,308	32,784
Profit + Opportunity	149,928	349,901	364,013	123,732	86,770	39,341
Inflation Factor	5.167	4.167	3.167	2.167	1.167	0.167
Inflated costs	192,916	428,786	424,838	137,531	91,853	39,663

#### Step by Step Calculations

Divide the new costs by the obsolescence factor Number of days from the accounting period end to the valuation date = 61 days Enhancement factor = 0.167 to increase the costs from June to August For 2023 divide by  $(1 + 0.10) \land 0.167 = 1.016$ For 2022 divide by  $(1 + 0.10) \land 1.167 = 1.118$ Then continue back to 2018

Totals	124,940	291,584	303,344	103,110	72,308	32,784
Profit + Opportunity	149,928	349,901	364,013	123,732	86,770	39,341
Inflation Factor	5.167	4.167	3.167	2.167	1.167	0.167
Inflated costs	192,916	428,786	424,838	137,531	91,853	39,663
Obsolescence	117,894	288,242	314,147	111,867	82,185	39,036

Reproduction cost then equals the sum of the bottom line = € 953,371

## Accounting for tax and tax amortization benefit (TAB)

= € 953,371

#### Reproduction cost then equals



#### **Commentary on Calculations**

The inflation rate is taken at 5% per annum, more accurately you would apply the inflation rate at the known yearly rate.

Obsolescence is taken at 10% per annum, this varies dependent upon the complexity of the algorithms.

The fair market value is very sensitive to the obsolescence For an obsolescence of 20% the fair value becomes €539,752

## Case study 3 – Teaching material (copyright)

Teaching material – new way of teaching medical students – saves Medical universities cost;

Your university medical school has developed a blended teaching software package along with online real time assessment for medical students. The software is a gamification of traditional lecture theatre training with cost savings as shown on the next slide:

#### Medical School Cost Savings 2023-2028



(i)

Lecture theatre time saved = 200 hours per annum

Marking and assessment time saved = 500 hours per annum

Blended cost of teaching staff $=$ \$250 per hour	(includes overheads)

Blended cost of marking staff = \$ 50 per hour (includes overheads)

Y Total cost saving = 
$$(200 \times 250) + (500 \times 50) = 75,000$$
 per annum

#### **Input Parameters for Valuation**

Adjustments	Тах
-------------	-----

Growth rate	5% pa	Corporation Tax	25%
Terminal growth rate	1%	Tax Amortization period	25 years
Discount rate	20%	Annuity	4.947587
Valuation date	29/08/2023	TAB factor	0.0520511
Financial year end	31/12/2023		
First cash flow	31/12/2023		

#### Step by Step Calculations

Year	2023	2024	2025	2026	2027	2028	Terminal
Saved costs	75,000	78,750	82,688	86,822	91,163	95,721	96,678
Taxes	18,750	19,688	20,672	21,705	22,791	23,930	24,170
After tax saved costs	56,250	59,063	62,016	65,116	68,372	71,791	72,509
Partial Period Adjustment	0.34	1	1	1	1	1	
	19,125	59,063	62,016	65,116	68,372	71,791	
Terminal Value						381,625	
	19,125	59,063	62,016	65,116	68,372	453,416	
Years for discounting	0.34	1.34	2.34	3.34	4.34	5.34	
Discount factor	0.94	0.78	0.65	0.54	0.45	0.38	
Present Value of saved costs	17,975	46,260	40,478	35,418	30,991	171,265	
Net Present Value	342,388						
ТАВ	17,822						
Fair Value	360,209						

WIPO FOR OFFICIAL USE ONLY

#### **Commentary on Calculations**

The discount rate is taken at 20%, this is high for a public university where the cost of capital is debt only, this figure is more like a small private university value.

For sensitivity calculations take the discount rate to 10%, then recalculate.

Result
--------

Net Preser	nt Value	485,246
TAB		48,525
Fair Value		533,771

A 48% increase in the expected lifetime value

#### **Licensing Considerations**



The total value of the NPV of the cost savings using the gamified teaching material = \$360,000.

The licensing university would expect 25% of this as a royalty = \$90,000

Or \$9,000 per annum over 10 years.

#### Spinouts and VC funding



Source: https://dougshapiro.medium.com/power-laws-in-culture-27ab6461c693

Venture capital works on a Power Law model

VCs – each investment is made with the potential of returning 10-20x (the whole fund or more)

Most of the investments will fail

A few will return the invested capital or a bit more

Outliers will return most of the fund

"A healthy intellectual property position may not guarantee a start-up technology company is going to be successful, but it is going to find it a whole lot harder to succeed if it does not have one. And crucially, it is not just the ownership of intellectual property that is important, it is the understanding that intellectual property is a key."

Joff Wild

#### Spinouts and VC funding – due diligence



### Spinouts and VC funding – valuation approaches

Early stages- VCs value company/not IP individually

• IP is included in the company value (main driver of value)

Pre & Post money valuation

The Art

- How much money one needs to raise? VCs usually want 20-30% equity
- Interest from other investors (FOMO) more leverage
- "We laugh at [venture] firms that use spreadsheets for seed and Series A deals for valuations. There's just not enough data." says Mendelson, co-author of the book, Venture Deals: Be Smarter Than Your Lawyer and Venture Capitalist.

Early stage - lack of historical financial data

<u>Premoney valuation =</u> <u>Postmoney valuation –</u> <u>Invested Capital</u>

Premoney valuation - €4m | 80% Postmoney valuation - €5m |100% Invested capital - €1m | 20%



#### Spinouts and VC funding – valuation approaches

3 semi-quantitative method (high degree of subjectivity) – Payne Scorecard, Berkus method, and Risk factor summation method.

• Example of Payne Scorecard

2 quantitative methods – VC method; First Chicago method.

• VC method
## Spinouts and VC funding – Payne scorecard

COMPARISON FACTOR	WEIGHT IN VALUATION
Strength of entrepreneur & Team	0-30%
Size of the opportunity	0-25%
Product/Technology	0-15%
Competitive environment	0-10%
Marketing/Sales/Partnerships	0-10%
Need for additional investment	0-5%
Other factors	0-5%

Develop for seed companies in the range of \$1m - \$2.5m – Premoney valuation.

Decide on comparison factor for potential company

Compare the factors with a benchmark company for which the Premoney valuation is known

Add factors and multiply with benchmark premoney valuation

Source: William Payne, The Definitive Guide to Raising Money from Angels; Antonella Puca, Early Stage Valuation: A Fair Value Perspective

WIPO

## Spinouts and VC funding – Payne scorecard

COMPARISON FACTOR	TARGET COMPANY	BENCHMARK	COMPARISON	FACTOR
Strength of entrepreneur & Team	30%	25%	120%	0.36
Size of the opportunity	25%	25%	100%	0.25
Product/Technology	15%	20%	75%	0.1125
Competitive environment	10%	10%	100%	0.1
Marketing/Sales/Partnerships	10%	12.5%	80%	0.08
Need for additional investment	5%	5%	100%	0.05
Other factors (great traction)	5%	2.5%	200%	0.1

Total factor – 1.0525; Benchmark Premoney valuation - \$2m

Target Premoney valuation - \$ 2.105m

## Spinouts and VC funding – VC method

Estimating – Postmoney valuation & ownership % - as a function of desired risk adjusted return & capital to invest

Postmoney valuation = Valuation at exit/(1+Target Return)<sup>Time to exit</sup>

Example

€1m to invest; Required return 40%

Value at exit -  $\in$  30m; Time to exit - 6 years

Target Total value to paid in capital (TVPI or Investment multiple) -  $(1+Target Return)^{Time to exit} - 7.53$ 

Postmoney valuation - €30m/7.53 – approx. €4m



Thank you for your attention!

DSava@mathys-squire.com BMore@mathys-squire.com

## © Mathys & Squire Consulting, 2023

© WIPO, 2023



Attribution 3.0 IGO

The CC license does not apply to non-WIPO content in this presentation.

Photo credits:

